Management of chemotherapy-induced nausea and vomiting: A pilot randomised controlled trial using Nevasic audio programme. (Manchester eScholar – The University of Manchester)

The findings from the trial highlight that conducting a non-pharmacological intervention using such an audio programme is feasible, although difficulties and limitations exist. This study did not detect any evidence for the effectiveness of Nevasic on CINV; however, the results show statistically significant less use of anti-emetics (post-chemotherapy) (p=0.03) and borderline non-significant (p=0.06) better global health status in Nevasic group.

via Management of chemotherapy-induced nausea and vomiting: A pilot randomised controlled trial using Nevasic audio programme. (Manchester eScholar – The University of Manchester).

Advertisements

Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study – Online First – Springer

The present study demonstrates that an antiemetic prophylaxis consisting of palonosetron and prednisolone is insufficient for the prevention of nausea and vomiting induced by radiotherapy and weekly cisplatin in patients treated for gynecological cancer. The addition of a neurokinin-1 receptor antagonist should be investigated in a randomized, double-blind study in this setting.

via Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study – Online First – Springer.

Willingness to Pay to Prevent Chemotherapy Induced Nausea and Vomiting Among Patients with Breast, Lung, or Colorectal Cancer, Journal of Medical Economics, Informa Healthcare

Cost contributed more to patient choices than any other single attribute. The combined effect of the likelihood, duration, and severity attributes for nausea, however, was a stronger driver of patient choices than cost, as was the combined effect of the likelihood, duration, and severity attributes for vomiting.

via Willingness to Pay to Prevent Chemotherapy Induced Nausea and Vomiting Among Patients with Breast, Lung, or Colorectal Cancer, Journal of Medical Economics, Informa Healthcare.

Access : A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy : British Journal of Cancer

Even with an increased dose of dexamethasone, aprepitant seemed more effective than placebo in these selected patients undergoing MEC; however, delayed phase management remains a significant problem.

via Access : A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy : British Journal of Cancer.

Access : A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy : British Journal of Cancer

Even with an increased dose of dexamethasone, aprepitant seemed more effective than placebo in these selected patients undergoing MEC; however, delayed phase management remains a significant problem.

via Access : A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy : British Journal of Cancer.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

The addition of 5mg/day of oral olanzapine to standard therapy can reduce the frequency of CINV and improve QOL of patients receiving highly or moderately emetogenic chemotherapy.

via Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study.

2013 International Symposium on Supportive Care in Cancer : The Lancet Oncology

Aprepitant is no better than dexamethasone for prevention of delayed emesis after use of anthracyclines and cyclophosphamide, say Fausto Roila (Terni, Italy) and colleagues.

via 2013 International Symposium on Supportive Care in Cancer : The Lancet Oncology.